Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BIOXCEL THERAPEUTICS INC (BTAI) Stock Price & Overview
NASDAQ:BTAI • US09075P2048
Current stock price
1.04 USD
-0.02 (-1.89%)
At close:
1.05 USD
+0.01 (+0.96%)
After Hours:
The current stock price of BTAI is 1.04 USD. Today BTAI is down by -1.89%. In the past month the price decreased by -22.39%. In the past year, price decreased by -41.57%.
BTAI Key Statistics
52-Week Range1.01 - 8.08
Current BTAI stock price positioned within its 52-week range.
1-Month Range1.01 - 1.42
Current BTAI stock price positioned within its 1-month range.
- Market Cap
- 28.153M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.71
- Dividend Yield
- N/A
BTAI Stock Performance
Today
-1.89%
1 Week
-9.57%
1 Month
-22.39%
3 Months
-34.59%
Longer-term
6 Months -49.27%
1 Year -41.57%
2 Years -97.42%
3 Years -99.68%
5 Years -99.81%
10 Years N/A
BTAI Stock Chart
BTAI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BTAI. When comparing the yearly performance of all stocks, BTAI is a bad performer in the overall market: 92.3% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BTAI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BTAI. BTAI has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BTAI Earnings
On March 27, 2026 BTAI reported an EPS of -0.58 and a revenue of 256.00K. The company beat EPS expectations (24.18% surprise) and beat revenue expectations (54.93% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.58
Revenue Reported256K
EPS Surprise 24.18%
Revenue Surprise 54.93%
BTAI Forecast & Estimates
11 analysts have analysed BTAI and the average price target is 13.06 USD. This implies a price increase of 1155.38% is expected in the next year compared to the current price of 1.04.
For the next year, analysts expect an EPS growth of 51.57% and a revenue growth 237.63% for BTAI
Analysts
Analysts78.18
Price Target13.06 (1155.77%)
EPS Next Y51.57%
Revenue Next Year237.63%
BTAI Financial Highlights
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -6.71. The EPS increased by 74.16% compared to the year before.
Income Statements
Revenue(TTM)642.00K
Net Income(TTM)-69.90M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%83.75%
Sales Q2Q%-30.05%
EPS 1Y (TTM)74.16%
Revenue 1Y (TTM)-71.67%
BTAI Ownership
Ownership
Inst Owners15.36%
Shares27.07M
Float26.14M
Ins Owners1.66%
Short Float %15.1%
Short Ratio2.22
BTAI Industry Overview
BTAI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
BTAI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BTAI
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
IPO: 2018-03-08
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 29
Phone: 12036438060
BIOXCEL THERAPEUTICS INC / BTAI FAQ
Can you describe the business of BIOXCEL THERAPEUTICS INC?
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Can you provide the latest stock price for BIOXCEL THERAPEUTICS INC?
The current stock price of BTAI is 1.04 USD. The price decreased by -1.89% in the last trading session.
Does BIOXCEL THERAPEUTICS INC pay dividends?
BTAI does not pay a dividend.
What is the ChartMill rating of BIOXCEL THERAPEUTICS INC stock?
BTAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about BIOXCEL THERAPEUTICS INC (BTAI) stock?
11 analysts have analysed BTAI and the average price target is 13.06 USD. This implies a price increase of 1155.38% is expected in the next year compared to the current price of 1.04.
Can you provide the number of employees for BIOXCEL THERAPEUTICS INC?
BIOXCEL THERAPEUTICS INC (BTAI) currently has 29 employees.
Can you provide the short interest for BTAI stock?
The outstanding short interest for BIOXCEL THERAPEUTICS INC (BTAI) is 15.1% of its float.